Skip to main content
. 2022 Oct 26;4(3):100423. doi: 10.1016/j.jtocrr.2022.100423

Figure 3.

Figure 3

CXCL10 fold change with vidutolimod and atezolizumab with and without RT in NSCLC. CXCL10 fold change was assessed in the serum samples collected after week 3 and week 8 vidutolimod injections in parts A (A) and B (B). aValues capped at 200 for plotting purposes. bMedians calculated based on maximal fold change from baseline after either week 3 or week 8 vidutolimod injections. CXCL10, C-X-C motif chemokine ligand 10; RT, radiation therapy.